150
Participants
Start Date
March 1, 2023
Primary Completion Date
May 1, 2025
Study Completion Date
May 1, 2025
physician's choice of chemotherapy
physician's choice of chemotherapy for relapsed/refractory ovarian clear cell carcinoma
immune checkpoint inhibitor based therapy
immune checkpoint inhibitor based therapy for relapsed/refractory ovarian clear cell carcinoma
RECRUITING
Tongji Hospital of Tongji Medical College, Huazhong University of Science and Technology, Wuhan
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
OTHER
Henan Cancer Hospital
OTHER_GOV
Qilu Hospital of Shandong University
OTHER
Hubei Cancer Hospital
OTHER
Anhui Provincial Cancer Hospital
OTHER
Peking University Cancer Hospital & Institute
OTHER
Hunan Province Tumor Hospital
OTHER
First Affiliated Hospital of Suzhou Medical College
OTHER
Shandong Tumor Hospital
OTHER
Chongqing University Cancer Hospital
OTHER
First Affiliated Hospital of Zhongshan Medical University
OTHER
Peking University Shenzhen Hospital
OTHER
Tongji Hospital
OTHER